Document Detail


Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group.
MedLine Citation:
PMID:  8840836     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Lipid-lowering therapy reduces cardiac morbidity and mortality. Less is known about its potential anti-ischemic effect. METHODS AND RESULTS: In a 2-year prospective randomized placebo-controlled study, the effect of pravastatin 40 mg on transient myocardial ischemia was assessed. Forty-eight-hour ambulatory ECGs with continuous ST-segment analysis were performed in 768 male patients with stable angina pectoris, documented coronary artery disease, and serum cholesterol between 4 and 8 mmol/L (155 and 310 mg/dL). During the trial, patients received routine antianginal treatment. In the patients randomized to pravastatin, transient myocardial ischemia was present at baseline in 28% and after treatment in 19%; in the placebo group, it was found in 20% and 23% of the patients, respectively (P = .021 for change in percentage between two treatment groups; odds ratio, 0.62; 95% CI, 0.41 to 0.93). Ischemic episodes decreased by 1.23 +/- 0.25 (SEM) episode with pravastatin and by 0.53 +/- 0.25 episode with placebo (P = .047). Under pravastatin, the duration of ischemia decreased from 80 +/- 12 minutes to 42 +/- 10 minutes (P = .017) and with placebo, from 60 +/- 13 minutes to 51 +/- 9 minutes (P = .56). The total ischemic burden decreased from 41 +/- 5 to 22 +/- 5 mm.min in the pravastatin group (P = .0058) and from 34 +/- 6 to 26 +/- 4 mm . min in the placebo group (P = .24). Adjusted for independent risk factors for the occurrence of ischemia, the effect of pravastatin on the reduction of risk for ischemia remained statistically significant (odds ratio, 0.45; 95% CI, 0.22 to 0.91; P = .026). CONCLUSIONS: In men with documented coronary artery disease and optimal antianginal therapy, pravastatin reduces transient myocardial ischemia.
Authors:
A J van Boven; J W Jukema; A H Zwinderman; H J Crijns; K I Lie; A V Bruschke
Related Documents :
1958676 - Dilated angiopathy: a specific subtype of allograft coronary artery disease.
8987266 - Three-dimensional mapping of acute ischemic regions using artificial neural networks an...
8678686 - Non-heart-beating donors: a model of thoracic allograft injury.
21930836 - Bright-blood t(2)-weighted mri has high diagnostic accuracy for myocardial hemorrhage i...
15300406 - Acute myocardial infarction in hemoglobin sc disease.
15050486 - Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  94     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1996-11-29     Completed Date:  1996-11-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1503-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, University Hospital Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angina Pectoris / drug therapy*
Anticholesteremic Agents / therapeutic use
Cardiovascular Agents / therapeutic use*
Cholesterol / blood
Drug Therapy, Combination
Electrocardiography, Ambulatory
Humans
Male
Middle Aged
Myocardial Ischemia / blood,  drug therapy*,  physiopathology
Pravastatin / therapeutic use*
Prospective Studies
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cardiovascular Agents; 57-88-5/Cholesterol; 81093-37-0/Pravastatin
Comments/Corrections
Comment In:
Circulation. 1997 Aug 5;96(3):1059-60   [PMID:  9264531 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Shaping the policy practice agenda of social work in the field of aging.
Next Document:  Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ven...